---
document_datetime: 2024-11-18 14:46:47
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lumigan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lumigan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 23.2011668
conversion_datetime: 2025-12-31 05:18:15.051654
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lumigan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0067              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | 15/11/2024                          |                                             | SmPC, Labelling and PL           |           |
| N/0066               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 20/07/2022                          |                                             | PL                               |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| T/0065            | Transfer of Marketing Authorisation                                                                                                                          | 29/04/2022   | 13/05/2022   | SmPC, Labelling and PL   |                                                                                                                                          |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/413/2 02103 | Periodic Safety Update EU Single assessment - bimatoprost                                                                                                    | 11/11/2021   | 20/01/2022   | SmPC and PL              | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/413/202103. |
| N/0063            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                             | 23/06/2021   | 20/01/2022   | PL                       |                                                                                                                                          |
| N/0062            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                             | 26/02/2021   | 21/04/2021   | PL                       |                                                                                                                                          |
| IA/0061           | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size | 02/10/2020   | n/a          |                          |                                                                                                                                          |
| IB/0060           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                               | 04/05/2020   | 21/04/2021   | Annex II and PL          |                                                                                                                                          |
| IB/0059           | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                       | 17/02/2020   | n/a          |                          |                                                                                                                                          |
| N/0058            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                             | 26/03/2019   | 21/04/2021   | PL                       |                                                                                                                                          |
| PSUSA/413/2 01803 | Periodic Safety Update EU Single assessment - bimatoprost                                                                                                    | 15/11/2018   | 18/01/2019   | SmPC and PL              | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/413/201803. |

<div style=\"page-break-after: always\"></div>

| IB/0057   | - Change in container closure system of the Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 04/09/2018   | 18/01/2019   | SmPC, Labelling and PL   | B.II.e.z Finished   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------|
| II/0055   | Submission of the final report of the Phase 4 clinical safety study P-192024-054 to evaluate the long- term safety of Lumigan 0.1 mg/ml compared with Lumigan 0.3 mg/ml and listed as a category 3 study in the RMP. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission competent authority                                                                                                                                                                                                                                                                                                                              | 26/04/2018   | n/a          |                          | of studies to the   |
| WS/1084/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.z - Quality change - Active substance - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 14/09/2017   | n/a          |                          |                     |

<div style=\"page-break-after: always\"></div>

| II/0052           | Update of the Lumigan 0.1 mg/ml eye drops SmPC section 4.8 to add the adverse reactions Eye discharge, Lacrimation increased, Eye oedema and Foreign body sensation in eyes in line with the Company Core Data Sheet. The Package Leaflet has been updated accordingly. Section 3 of the PL was also amended to improve clarity of instructions. In addition, the MAH took the opportunity to update the Product Information in line with the QRD template version 10 and implement the unique identifier 2D barcode. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 18/05/2017   | 12/04/2018   | SmPC, Annex II, Labelling and PL   |                                                                                                         |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|---------------------------------------------------------------------------------------------------------|
| IB/0051           | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/06/2016   | n/a          |                                    |                                                                                                         |
| N/0050            | Update of the package leaflet with revised contact details of the local representatives for Bulgaria, Czech Republic, Germany, Estonia, Greece, Cyprus, Spain, Iceland, Latvia, Lithuania, Hungary, Austria, Romania, and Slovak Republic. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                               | 02/03/2016   | 12/04/2018   | PL                                 |                                                                                                         |
| PSUSA/413/2 01503 | Periodic Safety Update EU Single assessment - bimatoprost                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 19/11/2015   | 14/01/2016   | SmPC and PL                        | Please refer to Lumigan PSUSA-00000413-201503 EPAR: Scientific conclusions and grounds recommending the |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             | variation to the terms of the marketing authorisation                                                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0048 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21/05/2015 | n/a        |             |                                                                                                                                   |
| N/0047    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 01/08/2014 | 14/01/2016 | PL          |                                                                                                                                   |
| PSUV/0046 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/10/2013 | 20/12/2013 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0046. |
| IB/0045/G | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.4.b - Change in the batch size (including batch | 15/11/2013 | n/a        |             |                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | down to 10-fold B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.3.z - Change in the manufacturing process of   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0044/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                          | 17/10/2013 | n/a |

<div style=\"page-break-after: always\"></div>

| II/0042   | Update of sections 4.3, 4.4 and 4.8 of the SmPC mainly in order to strengthen the existing warning on avoiding allowing the tip of the dispensing container to contact the eye. The Package Leaflet was updated accordingly. Additionally, the CHMP-recommended text for phosphate-containing eye drops has been included in the SmPC and PL. Furthermore, the PI is being brought in line with the latest QRD template version 9. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   | 19/09/2013   | 20/12/2013   | SmPC, Annex II, Labelling and PL   | The safety information in the SmPC for Lumigan was updated, to provide the most up to date safety guidance for Lumigan multi-dose eye drops solution, in order to prevent eye injuries while using the product. Additionally, text has been added to inform that, as for other eye drops containing phosphates, in very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0043    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 01/07/2013   | 20/12/2013   | PL                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0041   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                         | 21/03/2013   | 20/12/2013   | SmPC, Labelling and PL             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| T/0040    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 05/02/2013   | 25/02/2013   |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| N/0039    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15/02/2013   | 20/12/2013   | Labelling and PL                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0036/G | This was an application for a group of variations. To introduce two new presentations: two preservative free formulations of Lumigan 0.3 mg/ml, eye-drops, solution, in single-dose container                                                                                                                                                                                                                                                                                                                                                                                               | 18/10/2012   | 19/11/2012   | SmPC, Labelling and PL             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 30) Changes in the composition of the finished product - Other excipients or quantitative changes in one or more that may have a significant impact on the quality or efficacy of the product Replacement or addition of a manufacturing site for the FP - Secondary packaging Replacement or addition of a site for part or all of the process of the FP - Site where any manufacturing operation(s) take place, except batch batch control, and secondary packaging, for medicinal products (including those that are manufactured) excluding biological/ immunological medicinal products Change to batch release arrangements control testing of the FP - Replacement a site where batch control/testing Change in the specification parameters the finished product - Change specifications limits range Change in test procedure for the finished Other changes to a test procedure replacement or addition) Change in pack size of the finished Change in the number of units (e.g. ampoules, etc.) in a pack - Change outside   | (pack sizes 5 and   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| safety,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                     |
| B.II.b.1.a -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                     |
| site B.II.b.1.f -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                     |
| manufacturing manufacturing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                     |
| release, sterile                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                     |
| or addition of takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                     |
| B.II.d.1.e - and/or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                     |
| limits outside the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                     |
| of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                     |
| approved                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                     |

<div style=\"page-break-after: always\"></div>

|           | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                  |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0037 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                  | 31/10/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0035   | Update of sections 4.4, 4.5 and 4.8 of the Summary of Product Characteristics (SmPC) to include information in the SmPC for both Lumigan 0.1 mg/ml and 0.3 mg/ml in line with the recently amended Company Core Data Sheet and provide prescribers with up to date safety guidance. Sections 2, 3 and 4 of the Package Leaflet were updated accordingly. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 21/06/2012 | 23/07/2012 | SmPC, Annex II, Labelling and PL | The following updates of the Summary of product characteristics (SmPC) were considered relevant by the CHMP: 4.4 Special Warnings and Precautions section of the SmPC: - Addition of more information on darker iris colour - Addition of hair growth precaution - Addition of information on the consequences of more frequent than once a day administration - Addition of information relating to bacterial keratitis with multidose containers 4.5 Interactions with other medicinal products section - Addition of information on concomitant use of Lumigan with other prostaglandin analogues 4.8 Undesirable effects section - 'eye pain' was added as common side effect with Lumigan 0.1 mg/ml - 'periorbital erythema' as uncommon side effect with Lumigan 0.3 mg/ml |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                  |            |            |                 | - 'blurred vision' was added to the list of common side effects for Lumigan 0.3 mg/ml - 'pigmentation of periocular skin' was removed from table 2 in Lumigan 0.01% as it was redundant. The Package Leaflet was updated accordingly.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0034  | The Marketing Authorisation Holder (MAH) took the opportunity to update details of local representatives in Annex IIIB. Furthermore, Annex IIB was updated by deleting the DDPS version number. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 18/07/2011 | n/a        | Annex II and PL |                                                                                                                                                                                                                                         |
| N/0033  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                 | 21/01/2011 | n/a        | PL              |                                                                                                                                                                                                                                         |
| II/0031 | Introduction of a new active substance manufacturer B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is supported by an ASMF                                                               | 16/12/2010 | 04/01/2011 |                 |                                                                                                                                                                                                                                         |
| IA/0032 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                            | 26/11/2010 | n/a        |                 |                                                                                                                                                                                                                                         |
| II/0030 | Change in the control process for the finished product.                                                                                                                                                                                                                                          | 18/03/2010 | 24/03/2010 |                 |                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | Quality changes                                                                                                                                                   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029 | Inclusion of alternative packaging suppliers for Lumigan 0.03%. Quality changes                                                                                   | 18/02/2010 | 25/02/2010 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| X/0026  | Change or addition of a new strength/potency. Annex I_2.(c) Change or addition of a new strength/potency                                                          | 22/10/2009 | 07/01/2010 | SmPC, Annex II, Labelling and PL | The MAH applied for a new strength (Lumigan 0.1 mg/ml eye drops, solution) to provide a therapeutic alternative to the other approved formulation (0.3 mg/ml). The product line will now have two options, one with a reduced concentration of bimatoprost or one with a low benzalkonium chloride concentration. Choice between two formulations will depend on the patient's ocular status and ability to tolerate the product. The new presentation is aimed at improving the ocular surface tolerability, mainly conjunctival hyperaemia (redness of the eye), by reducing to one third the content of bimatoprost (i.e. from 0.03% to 0.01%). This leads to a 4-fold increase of the preservative BAK in order to achieve a greater absorption of the active substance. The CHMP considered the benefits of Lumigan 0.01% formulation outweigh the potential risks. |
| II/0028 | Update of Summary of Product Characteristics and Package Leaflet , mainly to update Section 4.8 of the SPC based on a recent update of the MAH's Core Data Sheet. | 23/07/2009 | 02/09/2009 | SmPC and PL                      | The rationale in support of the changes was based on a cumulative safety analysis of adverse events (collected up to 31 August 2008) as part of a revision of the Company Core Data Sheet for Lumigan. The review provided by the MAH was considered to be adequate and the MAH proposals                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | Update of Summary of Product Characteristics and Package Leaflet                                 |            |            |                     | were endorsed. The following two adverse events have been included: 'Nausea' and 'enophthalmos'. The following three adverse events have been deleted: 'Peripheral oedema', 'infection' (primarily colds and upper respiratory infections), and 'cataract'. In addition, aspects of section 4.4 concerning iris and periorbital tissue pigmentation have been updated. The recommendations on lactation in section 4.6 were also updated in line with the recommendations of the Guideline on risk assessment of medicinal products on human reproduction and lactation.   |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0027  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 27/02/2009 | n/a        | PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0024 | Change(s) to the test method(s) and/or specifications for the finished product                   | 19/03/2008 | 28/03/2008 |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| N/0025  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 05/03/2008 | n/a        | Labelling and PL    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| N/0023  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 09/08/2007 | n/a        | Labelling and PL    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0022 | IB_33_Minor change in the manufacture of the finished product                                    | 25/05/2007 | n/a        |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0021 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure   | 27/02/2007 | n/a        |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0020  | Renewal of the marketing authorisation.                                                          | 14/12/2006 | 20/02/2007 | SmPC, Labelling and | Based on their review of the available information and on the basis of a re-evaluation of the benefit risk balance, the                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                               |            |            | PL   | CHMP was of the opinion that the quality, safety and efficacy continue to be adequately and sufficiently demonstrated. Therefore, the benefit/risk profile of Lumigan continues to be favourable. The CHMP recommended the renewal of the Marketing Authorisation for Lumigan with unlimited validity.                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0019  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                              | 09/08/2006 | n/a        | PL   |                                                                                                                                                                                                                                                                                                                               |
| IB/0018 | IB_33_Minor change in the manufacture of the finished product                                                                                                                                 | 31/07/2006 | n/a        |      |                                                                                                                                                                                                                                                                                                                               |
| II/0017 | Update of Summary of Product Characteristics (section 4.8, Undesirable effects and section 4.4 Special Warnings and Special Precautions for Use) Update of Summary of Product Characteristics | 23/03/2006 | 27/04/2006 | SmPC | Further to their conclusions of the assessment of PSURs 4 and 5, the CHMP requested a variation to change the term \"Elevated liver function\" to the term \"liver function test abnormal\" and to amend the frequency grouping in section 4.8 (Undesirable effects) of the SPC, in accordance with the current Guideline on SPC. |
| IB/0016 | IB_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening IB_37_a_Change in the specification of the finished product - tightening of specification limits  | 13/12/2004 | n/a        |      |                                                                                                                                                                                                                                                                                                                               |
| N/0013  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                              | 09/07/2004 | n/a        | PL   |                                                                                                                                                                                                                                                                                                                               |
| IA/0015 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                                | 24/06/2004 | n/a        |      |                                                                                                                                                                                                                                                                                                                               |
| IA/0014 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                                | 24/06/2004 | n/a        |      |                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| N/0012   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                            | 10/05/2004   | n/a        |                                  |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|
| II/0008  | Extension of Indication Update of Summary of Product Characteristics and Package Leaflet                                                    | 22/10/2003   | 20/01/2004 | SmPC and PL                      |
| IA/0011  | IA_28_Change in any part of primary packaging material not in contact with finished product                                                 | 05/11/2003   | n/a        |                                  |
| I/0010   | 31_Change in container shape                                                                                                                | 05/08/2003   | 22/09/2003 |                                  |
| I/0009   | 25_Change in test procedures of the medicinal product                                                                                       | 16/06/2003   | 17/06/2003 |                                  |
| I/0007   | 15_Minor changes in manufacture of the medicinal product                                                                                    | 08/04/2003   | 08/04/2003 |                                  |
| I/0006   | 03_Change in the name and/or address of the marketing authorisation holder 01_Change in the name of a manufacturer of the medicinal product | 01/10/2002   | 23/10/2002 | SmPC, Labelling and PL           |
| I/0005   | 01_Withdrawal of the manufacturing authorisation for a site of manufacture                                                                  | 01/10/2002   | 07/10/2002 |                                  |
| I/0001   | 30_Change in pack size for a medicinal product                                                                                              | 17/05/2002   | 09/07/2002 | SmPC, Annex II, Labelling and PL |
| I/0004   | 23_Change in storage conditions                                                                                                             | 17/05/2002   | 27/05/2002 |                                  |

<div style=\"page-break-after: always\"></div>

| I/0003   | 31_Change in container shape                     | 17/05/2002   | 27/05/2002   |         |
|----------|--------------------------------------------------|--------------|--------------|---------|
| I/0002   | 15_Minor changes in manufacture of the medicinal | 17/05/2002   | 27/05/2002   | product |